Article
[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma].
Casopis lekaru ceskych - 1 Jan 2011
Dubská Lenka, Vyskocilová Martina, Nenutil Rudolf, Valík Dalibor, Knoflícková Dana, Fabian Pavel, Kocáková Ilona, Demlová Regina, Beránek Martin, Drastíková Monika, Vosmiková Hana, Bóday Arpád, Horká Katerina, Símová Jarmila, Drábek Jirí, Ehrmann Jirí, Hajdúch Marián, Matejcková Milada, Síma Radek, Tvrdík Daniel, Povýsil Ctibor, Ryska Ales
Abstract excerpt
Targeted therapy has become an integral part of treatment procedures of malignant tumors. Colorectal carcinomas are frequently targeted with monoclonal anti-EGFR antibodies (cetuximab and panitumumab). Activating somatic mutations in codons 12 and 13 of the exon 2 of KRAS gene are considered negative predictive factors of response to anti-EGFR therapy in patients with metastatic colorectal cancer. In the Czech...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.